# Arrowhead Pharmaceuticals clinical trials: 50 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 50 trials with Arrowhead Pharmaceuticals as lead sponsor, 8 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Arrowhead Pharmaceuticals: 50 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/arrowhead-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 50
- Recruiting or not yet: 8
- Read on: November 19, 2026

## Trials

The 25 newest of 50, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 6, 2026 | NCT07859813 | A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis | Arrowhead Pharmaceuticals | Phase 2 | Not yet recruiting | Metabolic Dysfunction-Associated Steatohepatitis | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859813) |
| June 23, 2026 | NCT07662096 | A First-In-Human Study of ARO-033 in Adult Participants | Arrowhead Pharmaceuticals | Phase 1 | Recruiting | Age-related Macular Degeneration | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662096) |
| March 16, 2026 | NCT07473843 | Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia | Arrowhead Pharmaceuticals | Phase 3 | Recruiting | Homozygous Familial Hypercholesterolemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473843) |
| November 21, 2025 | NCT07241546 | Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma | Arrowhead Pharmaceuticals | Phase 2 | Recruiting | Asthma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241546) |
| November 3, 2025 | NCT07223658 | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | Hyperlipidemia; Mixed | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223658) |
| October 27, 2025 | NCT07221344 | Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies | Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | Alzheimer Disease, Tauopathies, Frontotemporal Dementia, Progressive Supranuclear Palsy | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221344) |
| June 25, 2025 | NCT07037771 | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) | Arrowhead Pharmaceuticals | Phase 3 | Active not recruiting | Homozygous Familial Hypercholesterolemia | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037771) |
| April 22, 2025 | NCT06937203 | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | Obesity, Diabetes Mellitus, Type 2 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06937203) |
| March 18, 2025 | NCT06880770 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis | Arrowhead Pharmaceuticals | Phase 3 | Recruiting | Severe Hypertriglyceridemia | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06880770) |
| February 12, 2025 | NCT06822790 | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | Arrowhead Pharmaceuticals | Phase 3 | Active not recruiting | Hypertriglyceridemia | 710 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06822790) |
| January 28, 2025 | NCT06796426 | Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS | Arrowhead Pharmaceuticals | Not applicable | Available | Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG) | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06796426) |
| November 22, 2024 | NCT06700538 | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Arrowhead Pharmaceuticals | Phase 1/2 | Active not recruiting | Obesity | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06700538) |
| November 4, 2024 | NCT06672445 | Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | Arrowhead Pharmaceuticals | Phase 1 | Active not recruiting | Spinocerebellar Ataxia Type 2 | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06672445) |
| April 4, 2024 | NCT06347133 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | Arrowhead Pharmaceuticals | Phase 3 | Completed | Hypertriglyceridemia | 1,456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06347133) |
| April 4, 2024 | NCT06347016 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia | Arrowhead Pharmaceuticals | Phase 3 | Completed | Severe Hypertriglyceridemia | 311 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06347016) |
| April 4, 2024 | NCT06347003 | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | Arrowhead Pharmaceuticals | Phase 3 | Completed | Severe Hypertriglyceridemia | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06347003) |
| January 17, 2024 | NCT06209177 | Study of ARO-CFB in Adult Healthy Volunteers | Arrowhead Pharmaceuticals | Phase 1 | Completed | IgA Nephropathy | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06209177) |
| July 18, 2023 | NCT05949294 | Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) | Arrowhead Pharmaceuticals | Phase 1 | Withdrawn | Amyotrophic Lateral Sclerosis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05949294) |
| September 13, 2022 | NCT05537025 | Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis | Arrowhead Pharmaceuticals | Phase 1/2 | Completed | Idiopathic Pulmonary Fibrosis | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05537025) |
| September 9, 2022 | NCT05533294 | Study of ARO-RAGE in Healthy Subjects | Arrowhead Pharmaceuticals | Phase 1 | Completed | Asthma | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05533294) |
| June 9, 2022 | NCT05413135 | Study of ARO-APOC3 in Adults With Dyslipidemia | Arrowhead Pharmaceuticals | Phase 2 | Completed | Dyslipidemias | 418 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05413135) |
| March 23, 2022 | NCT05292950 | Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease | Arrowhead Pharmaceuticals | Phase 1/2 | Terminated | Asthma, Chronic Obstructive Pulmonary Disease | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05292950) |
| March 11, 2022 | NCT05276570 | Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease | Arrowhead Pharmaceuticals | Phase 1/2 | Completed | Asthma | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05276570) |
| February 1, 2022 | NCT05217667 | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) | Arrowhead Pharmaceuticals | Phase 2 | Terminated | Homozygous Familial Hypercholesterolemia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05217667) |
| October 22, 2021 | NCT05089084 | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) | Arrowhead Pharmaceuticals | Phase 3 | Completed | Familial Chylomicronemia | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05089084) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 1/2 | 11 |
| Phase 2 | 17 |
| Phase 3 | 8 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Terminated | 11 |
| Recruiting | 7 |
| Active not recruiting | 4 |
| Withdrawn | 3 |
| Not yet recruiting | 1 |
| Available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertriglyceridemia | 8 |
| Hepatitis B | 8 |
| alpha 1-Antitrypsin Deficiency | 5 |
| Asthma | 4 |
| Hyperlipoproteinemia Type II | 3 |
| Homozygous Familial Hypercholesterolemia | 3 |
| Hepatitis B, Chronic | 3 |
| Dyslipidemias | 3 |
| Hyperlipoproteinemia Type I | 3 |
| Glomerulonephritis, IGA | 2 |
| Obesity | 2 |
| Idiopathic Pulmonary Fibrosis | 1 |
| Cystic Fibrosis | 1 |
| Amyotrophic Lateral Sclerosis | 1 |
| Lipid Metabolism, Inborn Errors | 1 |
| Metabolism, Inborn Errors | 1 |
| Genetic Diseases, Inborn | 1 |
| Congenital, Hereditary, and Neonatal Diseases and Abnormalities | 1 |
| Hyperlipoproteinemias | 1 |
| Hyperlipidemias | 1 |
| Lipid Metabolism Disorders | 1 |
| Metabolic Diseases | 1 |
| Nutritional and Metabolic Diseases | 1 |
| Hepatitis | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Propane suppliers in the United States](https://specstream.ai/data/businesses/propane-suppliers/united-states)
- [Mexican restaurants in the United States](https://specstream.ai/data/businesses/mexican-restaurants/united-states)
- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [Child psychiatry practices in the United States](https://specstream.ai/data/businesses/child-psychiatry-practices/united-states)
